Page 8 - Objective Response Rate News Today

Everest Medicines returned rights for Trodelvy to Immunomedics. Nanchang Jemincare out-licensed global rights for its prostate cancer candidate to Genentech in a $650 million deal.

SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer

Investegate announcements from Hutchmed China Ltd, Preliminary results from SAVANNAH Phase 2 Trial

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 -- Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse... | July 6, 2022

Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing Chinas first immunotherapy bi-specific antibody approved for...

CRISPR Therapeutics shares traded as high as $200 18 months ago, but today the share price is $62, and market cap valuation $4.75bn. Read about CRSP here.

Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla.

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate –– 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles –– 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event –– 83% Reported Grade 3 Adverse Events of Special Intere...

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) --  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...

G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace